Oragenics, Inc. (OGEN)
USD 0.33
(-2.99%)
USD 0.33
(-2.99%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 5.45 Million USD | -62.54% |
| 2022 | 14.55 Million USD | -8.24% |
| 2021 | 15.85 Million USD | -40.48% |
| 2020 | 26.64 Million USD | 67.79% |
| 2019 | 15.87 Million USD | 58.87% |
| 2018 | 9.99 Million USD | 48.78% |
| 2017 | 6.71 Million USD | -21.35% |
| 2016 | 8.54 Million USD | -30.81% |
| 2015 | 12.34 Million USD | 93.31% |
| 2014 | 6.38 Million USD | -62.21% |
| 2013 | 16.89 Million USD | 31.15% |
| 2012 | 12.88 Million USD | 59.53% |
| 2011 | 8.07 Million USD | -2.68% |
| 2010 | 8.29 Million USD | 22.93% |
| 2009 | 6.75 Million USD | 7.72% |
| 2008 | 6.26 Million USD | 153.52% |
| 2007 | 2.47 Million USD | -18.35% |
| 2006 | 3.02 Million USD | -7.23% |
| 2005 | 3.26 Million USD | -1.71% |
| 2004 | 3.32 Million USD | 99.1% |
| 2003 | 1.66 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 2.3 Million USD | -6.26% |
| 2024 Q1 | 2.46 Million USD | -2.49% |
| 2023 Q3 | 2.09 Million USD | -32.64% |
| 2023 Q1 | 2.9 Million USD | 486.11% |
| 2023 Q2 | 3.1 Million USD | 7.04% |
| 2023 Q4 | 2.52 Million USD | 20.45% |
| 2023 FY | 10.64 Million USD | -26.87% |
| 2022 FY | 14.55 Million USD | -8.24% |
| 2022 Q3 | 3.95 Million USD | -2.31% |
| 2022 Q4 | 495.6 Thousand USD | -87.47% |
| 2022 Q1 | 6.05 Million USD | 153.53% |
| 2022 Q2 | 4.04 Million USD | -33.15% |
| 2021 Q3 | 4.39 Million USD | 14.48% |
| 2021 Q4 | 2.38 Million USD | -45.65% |
| 2021 Q1 | 5.23 Million USD | 15.13% |
| 2021 Q2 | 3.83 Million USD | -26.72% |
| 2021 FY | 15.85 Million USD | -40.48% |
| 2020 FY | 26.64 Million USD | 67.79% |
| 2020 Q2 | 12.35 Million USD | 136.09% |
| 2020 Q1 | 5.23 Million USD | 43.01% |
| 2020 Q4 | 4.54 Million USD | 0.9% |
| 2020 Q3 | 4.5 Million USD | -63.5% |
| 2019 Q4 | 3.65 Million USD | -6.68% |
| 2019 FY | 15.87 Million USD | 58.87% |
| 2019 Q3 | 3.92 Million USD | -20.07% |
| 2019 Q1 | 3.39 Million USD | 20.17% |
| 2019 Q2 | 4.9 Million USD | 44.5% |
| 2018 FY | 9.99 Million USD | 48.78% |
| 2018 Q2 | 2.28 Million USD | 7.63% |
| 2018 Q4 | 2.82 Million USD | 2.17% |
| 2018 Q3 | 2.76 Million USD | 21.06% |
| 2018 Q1 | 2.12 Million USD | 50.24% |
| 2017 Q2 | 1.39 Million USD | -29.73% |
| 2017 Q1 | 1.98 Million USD | -26.6% |
| 2017 Q4 | 1.41 Million USD | -26.5% |
| 2017 Q3 | 1.92 Million USD | 37.57% |
| 2017 FY | 6.71 Million USD | -21.35% |
| 2016 Q4 | 2.7 Million USD | 33.61% |
| 2016 FY | 8.54 Million USD | -30.81% |
| 2016 Q3 | 2.02 Million USD | 16.93% |
| 2016 Q2 | 1.73 Million USD | -22.48% |
| 2016 Q1 | 2.23 Million USD | -4.61% |
| 2015 Q3 | 2.02 Million USD | -68.78% |
| 2015 FY | 12.34 Million USD | 93.31% |
| 2015 Q4 | 2.34 Million USD | 15.76% |
| 2015 Q2 | 6.48 Million USD | 334.67% |
| 2015 Q1 | 1.49 Million USD | 9.7% |
| 2014 Q3 | 1.16 Million USD | -44.15% |
| 2014 FY | 6.38 Million USD | -62.21% |
| 2014 Q1 | 1.78 Million USD | -47.97% |
| 2014 Q2 | 2.08 Million USD | 16.64% |
| 2014 Q4 | 1.36 Million USD | 17.04% |
| 2013 FY | 16.89 Million USD | 31.15% |
| 2013 Q3 | 9.46 Million USD | 338.97% |
| 2013 Q1 | 1.84 Million USD | -8.25% |
| 2013 Q4 | 3.42 Million USD | -63.78% |
| 2013 Q2 | 2.15 Million USD | 16.65% |
| 2012 Q4 | 2.01 Million USD | -8.28% |
| 2012 Q1 | 1.66 Million USD | -19.23% |
| 2012 FY | 12.88 Million USD | 59.53% |
| 2012 Q2 | 7.01 Million USD | 322.16% |
| 2012 Q3 | 2.19 Million USD | -68.68% |
| 2011 Q1 | 1.77 Million USD | -17.06% |
| 2011 Q4 | 2.05 Million USD | 6.73% |
| 2011 Q2 | 2.32 Million USD | 31.22% |
| 2011 FY | 8.07 Million USD | -2.68% |
| 2011 Q3 | 1.92 Million USD | -17.05% |
| 2010 Q2 | 2.18 Million USD | 15.63% |
| 2010 FY | 8.29 Million USD | 22.93% |
| 2010 Q4 | 2.13 Million USD | 2.22% |
| 2010 Q1 | 1.89 Million USD | 29.51% |
| 2010 Q3 | 2.08 Million USD | -4.51% |
| 2009 Q4 | 1.46 Million USD | -8.36% |
| 2009 FY | 6.75 Million USD | 7.72% |
| 2009 Q1 | 2.09 Million USD | -29.7% |
| 2009 Q2 | 1.6 Million USD | -23.29% |
| 2009 Q3 | 1.59 Million USD | -0.75% |
| 2008 Q3 | 1.25 Million USD | 12.74% |
| 2008 Q1 | 926.09 Thousand USD | 28.94% |
| 2008 FY | 6.26 Million USD | 153.52% |
| 2008 Q4 | 2.97 Million USD | 137.54% |
| 2008 Q2 | 1.11 Million USD | 20.03% |
| 2007 Q2 | 622.96 Thousand USD | 6.66% |
| 2007 Q1 | 584.07 Thousand USD | -19.65% |
| 2007 Q4 | 718.25 Thousand USD | 32.44% |
| 2007 Q3 | 542.32 Thousand USD | -12.95% |
| 2007 FY | 2.47 Million USD | -18.35% |
| 2006 Q2 | 801.83 Thousand USD | -7.32% |
| 2006 Q4 | 726.9 Thousand USD | 14.63% |
| 2006 Q3 | 634.13 Thousand USD | -20.91% |
| 2006 FY | 3.02 Million USD | -7.23% |
| 2006 Q1 | 865.13 Thousand USD | 13.83% |
| 2005 Q3 | 750 Thousand USD | -14.28% |
| 2005 Q1 | -879.1 Thousand USD | -167.22% |
| 2005 FY | 3.26 Million USD | -1.71% |
| 2005 Q2 | 874.96 Thousand USD | 199.53% |
| 2005 Q4 | 760 Thousand USD | 1.33% |
| 2004 Q2 | 723.2 Thousand USD | 232.83% |
| 2004 Q1 | -544.46 Thousand USD | -186.53% |
| 2004 Q3 | 745.56 Thousand USD | 3.09% |
| 2004 Q4 | 1.3 Million USD | 75.4% |
| 2004 FY | 3.32 Million USD | 99.1% |
| 2003 Q2 | 432.44 Thousand USD | 108.0% |
| 2003 Q4 | 629.18 Thousand USD | 57.92% |
| 2003 FY | 1.66 Million USD | 0.0% |
| 2003 Q3 | 398.42 Thousand USD | -7.87% |
| 2003 Q1 | 207.89 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 32.07 Million USD | 83.003% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | 41.174% |
| Armata Pharmaceuticals, Inc. | 11.64 Million USD | 53.198% |
| Actinium Pharmaceuticals, Inc. | 52 Million USD | 89.516% |
| Azitra, Inc. | 8.3 Million USD | 34.333% |
| Can-Fite BioPharma Ltd. | 8.93 Million USD | 39.003% |
| Chromocell Therapeutics Corporation | 6.86 Million USD | 20.552% |
| Calidi Biotherapeutics, Inc. | 28.99 Million USD | 81.195% |
| CEL-SCI Corporation | 31.47 Million USD | 82.679% |
| iBio, Inc. | 16.85 Million USD | 67.661% |
| Lineage Cell Therapeutics, Inc. | 33 Million USD | 83.482% |
| MAIA Biotechnology, Inc. | 20.18 Million USD | 72.987% |
| Matinas BioPharma Holdings, Inc. | 24.86 Million USD | 78.071% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | 60.866% |
| NovaBay Pharmaceuticals, Inc. | 12.89 Million USD | 57.73% |
| NanoViricides, Inc. | 8.51 Million USD | 35.981% |
| BiomX Inc. | 26.81 Million USD | 79.668% |
| BiomX Inc. | 26.81 Million USD | 79.668% |
| Protalix BioTherapeutics, Inc. | 32.05 Million USD | 82.99% |
| Palatin Technologies, Inc. | 34.67 Million USD | 84.275% |
| Scorpius Holdings, Inc. | 39.81 Million USD | 86.307% |